Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2019-06-04 Investor Presentation
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science fournit un résumé de la conférence web qui s’est tenue le 4 juin 2019
Investor Presentation Classification · 1% confidence The document is a summary of a web conference held on June 4, 2019, detailing AB Science's clinical programs, specifically for ALS and mastocytosis, including updates on Phase 2/3 and planned Phase 3 confirmatory studies, regulatory interactions (ANSM, EMA), and intellectual property. This content—a detailed update on clinical trial progress, regulatory status, and future plans presented to investors/analysts—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a transcript (CT), but rather a strategic presentation of data and outlook.
2019-06-04 French
AB Science is providing a summary of the web conference held on 4 June 2019
Investor Presentation Classification · 1% confidence The document is titled "AB Science outlook for 2019 - Summary of webcast part 1" and provides detailed updates on clinical programs (ALS and Mastocytosis), including results from Phase 2/3 studies, plans for Phase 3 confirmatory studies, regulatory interactions (ANSM, EMA), competitive landscape, and intellectual property status. This content structure—a summary of ongoing research, clinical trial progress, and future outlook presented via a webcast—is characteristic of an Investor Presentation (IP) or a detailed update often accompanying an earnings release, but the focus here is on clinical/pipeline progress rather than just financial results. Since it is a summary of a webcast providing in-depth clinical and strategic updates to investors, it aligns best with the Investor Presentation (IP) category, which covers financials, strategy, and market position in detail, often derived from such presentations.
2019-06-04 English
AB Science organise une conférence web sur ses perspectives de l’année 2019, les 4 et 5 juin 2019, de 17h30 à 19h00 (heure de Paris)
Report Publication Announcement Classification · 1% confidence The document is a press release dated May 30, 2019, announcing that AB Science will host a web conference on June 4th and 5th, 2019, to discuss its 2019 outlook, specifically detailing the development programs for its drug masitinib and introducing a new molecule, AB8939. This content—announcing an event where management will discuss strategy, pipeline progress, and future outlook—is characteristic of an Investor Presentation (IP) or a general update aimed at investors. Since it is an announcement of an event where detailed information will be presented, and it is not a formal regulatory filing like a 10-K or an earnings release (ER), the most fitting category is Investor Presentation (IP), as the web conference agenda mirrors the structure of an investor presentation. It is not an Earnings Release (ER) because it focuses on pipeline development and future outlook rather than reporting past financial results. It is not a Report Publication Announcement (RPA) because it is announcing a future event (a conference call) where information will be shared, not announcing the publication of a static report.
2019-05-30 French
AB Science will hold a web conference on its outlook for 2019 on June 4 and 5, 2019 from 5.30 pm to 7pm CET
Report Publication Announcement Classification · 1% confidence The document is an announcement from AB Science detailing an upcoming web conference scheduled for June 4 and 5, 2019. The purpose of the conference is to communicate the company's 'outlook for 2019,' covering updates on clinical development programs (masitinib and AB8939), expected results calendars, and Q&A sessions. This format—an announcement inviting participation in a discussion about future plans, results, and strategy—is characteristic of an investor relations event, often preceding or accompanying an earnings release or strategy update. Since it is an announcement about a scheduled event where management will discuss performance and outlook, it most closely aligns with the content discussed during an Earnings Call. Therefore, the document itself is best classified as a Call Transcript (CT) if it were the transcript, but since this is the *announcement* of the call, and it details the agenda for a discussion that will likely cover financial performance and outlook, it is highly related to the content of an Earnings Release (ER) or a Call Transcript (CT). Given the detailed agenda covering clinical pipelines and future outlook, it functions as a precursor to a formal earnings discussion. However, the text is an invitation and agenda for a web conference, which is essentially a scheduled call. If the full transcript were provided, it would be 'CT'. Since this is the announcement/invitation, and it details the content of a management discussion, it is most similar in nature to the material presented during an earnings call. In many databases, the announcement of an earnings call or investor presentation is often categorized based on the primary content discussed. Since the content is a detailed review of development programs and outlook, it strongly suggests an investor/earnings-related call. Given the options, and the fact that it is an announcement about a call where management will discuss performance and outlook, 'CT' (Call Transcript) is the closest fit for the *type* of event being announced, although technically this is an announcement *about* a call. If 'CT' is reserved strictly for the transcript, 'ER' (Earnings Release) covers the financial outlook discussion, or 'IP' (Investor Presentation) covers the presentation aspect. Since the structure is a detailed agenda for a two-day discussion, it functions like a detailed investor presentation or a call. Given the detailed review of clinical programs and outlook, 'IP' (Investor Presentation) is a strong candidate, but 'CT' covers the format (web conference/call). Since the content is highly specific to pipeline updates and outlook, which often accompanies earnings, I will lean towards the format of the event being announced. However, looking at the definitions, 'CT' is for the full text transcript. This is an announcement. 'ER' is for the initial announcement of results. This is an announcement about an *outlook* discussion. 'IP' is for a detailed presentation. This agenda looks like the structure of an investor presentation or call. I will classify this as an Investor Presentation (IP) as it details the content to be presented to investors over two days, which is more specific than a general Regulatory Filing (RNS) or Report Publication Announcement (RPA), as the document itself contains substantial content outlining the discussion points, not just announcing a separate report. Revisiting the 'MENU VS MEAL' rule: This document is substantial (5764 chars) and contains detailed information about the agenda, not just a brief notice saying 'the presentation is attached'. Therefore, it is not RPA or RNS. It is the content outlining the discussion points for an investor event. 'IP' (Investor Presentation) fits best for a detailed agenda outlining strategy and pipeline review for investors.
2019-05-30 English
AB Science announces the lifting of the ANSM clinical hold
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science announcing that the French regulatory body (ANSM) has lifted the clinical hold on their studies. This is a specific, material event related to drug development and regulatory compliance, but it is not a comprehensive financial report (like 10-K or IR), an earnings announcement (ER), or a formal shareholder communication (like DEF 14A or AGM-R). It is an announcement concerning a significant operational/legal/regulatory matter impacting the company's pipeline. Since it details a regulatory action (lifting a clinical hold) and is presented as a news update, it fits best under the general category for regulatory announcements that don't fit the highly specific financial or corporate governance codes. Given the options, 'Regulatory Filings' (RNS) serves as the most appropriate fallback for significant, non-financial, non-governance regulatory updates, although 'Legal Proceedings Report' (LTR) could be considered if the hold was purely legal, but this is a health safety agency action. RNS is the best fit for a general regulatory update press release.
2019-05-28 English
AB Science annonce la levée de la décision de suspension des études cliniques par l’ANSM
Regulatory Filings Classification · 1% confidence The document is a press release dated May 28, 2019, announcing that the French National Agency for the Safety of Medicines and Health Products (ANSM) has lifted the suspension of clinical studies for AB Science. This is a specific operational update concerning regulatory interaction and clinical trials, not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a formal shareholder vote result (DVA). It is an announcement regarding a significant regulatory event impacting the company's operations. While it is a regulatory announcement, it is highly specific to legal/regulatory proceedings concerning clinical trials, which aligns closely with the scope of 'Legal Proceedings Report' (LTR) if interpreted broadly to include regulatory actions impacting operations, or it could be classified as a general 'Regulatory Filing' (RNS) if LTR is strictly reserved for lawsuits. Given the context of regulatory action (ANSM decision) and the nature of the update (lifting a suspension), it is best categorized as a specific regulatory/legal event update. However, since it is not a lawsuit but a regulatory decision affecting clinical development, and there isn't a perfect 'Clinical Trial Update' category, 'LTR' (Legal Proceedings Report) is often used for significant regulatory actions/decisions impacting the company's status, or 'RNS' as a general regulatory announcement. Since the core issue is the lifting of a regulatory hold on clinical studies, which is a significant legal/regulatory development, LTR is a plausible fit, but RNS is the safest fallback for non-standard announcements. Given the content focuses on regulatory compliance and the lifting of a suspension, it is a specific regulatory update. I will classify it as RNS as it is a general regulatory announcement that doesn't fit the other specific financial or corporate governance codes, although it touches upon regulatory compliance.
2019-05-28 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.